XOMA Corporation
XOMA today announced its partner, Servier, has initiated the first
Servier-sponsored proof-of-concept study in a cardiovascular indication. The
study has opened for patient enrollment. The study is expected to enroll 45
patients who have experienced Acute Coronary Syndrome (ACS) in the past three
to twelve months. The objective of this study is to evaluate the effect of
subcutaneous administration of 30 mg gevokizumab as compared to placebo in
reducing arterial wall inflammation in patients with marked atherosclerotic
plaque inflammation. The primary endpoint Servier will be assessing is the
change in the mean target to background ratio (TBR) of the radioactive tracer
FDG assessed by PET/CT after three months of treatment. The study also will
determine gevokizumab's effect on a number of cardiac and vascular biological
blood biomarkers.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in